Sulfalene


Concise Prescribing Info
Indications/Uses
Listed in Dosage.
Dosage/Direction for Use
Adult : PO Resp tract infections; UTI 2 g/wk as a single dose. Malaria Per tab contains sulfalene 500 mg and pyrimethamine 25 mg: 3 tab as a single dose.
Dosage Details
Oral
Malaria
Adult: As combination of sulfalene 500 mg and pyrimethamine 25 mg per tablet: 3 tablets as a single dose.

Oral
Respiratory tract infections, Urinary tract infections
Adult: 2 g as a single dose once a wk.
Renal Impairment
Oral:
Respiratory tract infections,Urinary tract infections: Dose reduction may be needed.
Hepatic Impairment
Oral:
Respiratory tract infections,Urinary tract infections: Dose reduction may be needed.
Contraindications
Severe renal or hepatic failure; blood disorders; hypersensitivity to sulfonamides; acute porphyria; SLE. Pregnancy (3rd trimester) and lactation; infants ≤2 mth.
Special Precautions
Renal or hepatic impairment; history of allergy or asthma; AIDS; G6PD deficiency (at risk of haemolytic reactions); elderly; ensure adequate fluid intake to reduce risk of crystalluria. Discontinue if rash occurs.
Adverse Reactions
Nausea, vomiting, anorexia, diarrhoea, hypersensitivity reactions, SLE, serum sickness-like syndrome, liver necrosis and hepatomegaly, myocarditis, pulmonary eosinophilia and fibrosing alveolitis, vasculitis, hypoglycaemia, hypothyroidism, neurological reactions, jaundice and kernicterus in premature neonates. Pseudomembranous colitis.
Potentially Fatal: Blood dyscrasias, Stevens-Johnson syndrome, toxic epidermal necrolysis, anaphylaxis.
Drug Interactions
Potentiates effects of oral anticoagulants, methotrexate, phenytoin. Increased risk of crystalluria with compounds that render the urine acidic.
Lab Interference
Interference with tests for urea, creatinine, urinary glucose and urobilinogen.
Action
Description: Sulfalene is a long-acting sulfonamide also known as sulfametopyrazine. It interferes with the synthesis of nucleic acids in sensitive organisms by blocking the conversion of p-aminobenzoic acid (PABA) to the co-enzyme dihydrofolic acid. Its action is bacteriostatic, although bactericidal effects may be exerted where concentrations of thymine are low in the surrounding medium.
Pharmacokinetics:
Absorption: Readily absorbed from GI tract.
Distribution: Protein binding: 60-80%.
Metabolism: 5% of dose metabolised to acetyl derivative.
Excretion: Excreted slowly via urine. Biological half life: 60-65 hr.
MIMS Class
Disclaimer: This information is independently developed by MIMS based on Sulfalene from various references and is provided for your reference only. Therapeutic uses, prescribing information and product availability may vary between countries. Please refer to MIMS Product Monographs for specific and locally approved prescribing information. Although great effort has been made to ensure content accuracy, MIMS shall not be held responsible or liable for any claims or damages arising from the use or misuse of the information contained herein, its contents or omissions, or otherwise. Copyright © 2020 MIMS. All rights reserved. Powered by MIMS.com
Register or sign in to continue
Asia's one-stop resource for medical news, clinical reference and education
Sign up for free
Already a member? Sign in